157 related articles for article (PubMed ID: 34657048)
1. [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer].
Sumiyoshi T; Akamatsu S
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1203-1208. PubMed ID: 34657048
[TBL] [Abstract][Full Text] [Related]
2. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
3. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract][Full Text] [Related]
4. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
6. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
[TBL] [Abstract][Full Text] [Related]
9. Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
Devlies W; Eckstein M; Cimadamore A; Devos G; Moris L; Van den Broeck T; Montironi R; Joniau S; Claessens F; Gevaert T
Cells; 2020 Nov; 9(11):. PubMed ID: 33212909
[TBL] [Abstract][Full Text] [Related]
10.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
11. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review.
Baboudjian M; Peyrottes A; Dariane C; Fromont G; Denis JA; Fiard G; Kassab D; Ladoire S; Lehmann-Che J; Ploussard G; Rouprêt M; Barthélémy P; Roubaud G; Lamy PJ
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38824003
[TBL] [Abstract][Full Text] [Related]
12. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Tulpule V; Morrison GJ; Falcone M; Quinn DI; Goldkorn A
Curr Oncol Rep; 2022 Oct; 24(10):1287-1298. PubMed ID: 35575959
[TBL] [Abstract][Full Text] [Related]
13. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
14. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
Barnett ES; Schultz N; Stopsack KH; Lam ET; Arfe A; Lee J; Zhao JL; Schonhoft JD; Carbone EA; Keegan NM; Wibmer A; Wang Y; Solit DB; Abida W; Wenstrup R; Scher HI
Eur Urol; 2023 Feb; 83(2):112-120. PubMed ID: 36123219
[TBL] [Abstract][Full Text] [Related]
15. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer.
Plata Bello A; Tamayo Jover MA; Gutierrez Nicolas F; Acosta López S; Concepción Masip T; Plata Bello J
Arch Esp Urol; 2022 Mar; 75(2):195-202. PubMed ID: 35332889
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.
González-Billalabeitia E; Conteduca V; Wetterskog D; Jayaram A; Attard G
Prostate Cancer Prostatic Dis; 2019 May; 22(2):195-205. PubMed ID: 30413805
[TBL] [Abstract][Full Text] [Related]
19. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.
de Jong AC; Isebia KT; Ling SW; de Weerd V; Van NM; Kraan J; Martens JWM; Mehra N; Hamberg P; Lolkema MP; de Wit R; van der Veldt AAM; Wilting SM
JCO Precis Oncol; 2023 Sep; 7():e2300156. PubMed ID: 38061007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
